Andexanet alfa is currently under regulatory review by the European Union and is undergoing clinical development in Japan 1.Īndexanet alfa works by binding to Factor Xa inhibitors and prevent them from interacting with endogenous Factor Xa. However, the use of these agents is associated with a risk for uncontrollable bleeding episodes that can lead to can cause serious or fatal bleeding. Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism. It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with rivaroxaban and apixaban in cases of life-threatening or uncontrolled bleeding. It was developed by Portola Pharmaceuticals and was approved in in May 2018.

Andexxa Generic Name Andexanet alfa DrugBank Accession Number DB14562 BackgroundĪndexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation.

Andexxa prescribing information